TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main Inclusion Criteria:~* Written informed consent~* Diagnosis of persistent chronic bronchial asthma, according to Global Initiative for Asthma (GINA) guidelines~* The patient has been receiving BDP - CFC ≤1000 mcg per day or equivalent for the previous four weeks~* FEV1 between 60 and 90% predicted at visit 1~* No change in asthma treatment within 4 weeks prior to visit 1~Main Exclusion Criteria:~* Patients with poorly controlled asthma defined as requiring a course of oral or parenteral corticosteroids, admission to hospital for asthma (including treatment in an emergency room), or exacerbation of asthma in the four weeks prior to visit 1~* Patients who suffer from seasonal asthma alone or patients who are likely to have a major exacerbation of their asthma due to seasonal effects during the study run-in or treatment period~* A history of lower airway infection in the four weeks prior to visit 1~* A diagnosis of chronic obstructive pulmonary disease (COPD) and/or other relevant lung disease (e.g. cystic fibrosis, bronchiectasis)~* Heavy smoker currently smoking \>20 cigarettes per day and/or \>10 pack years or the patient is an ex-smoker who has smoked \>10 pack years~* Patients using \>8 puffs/day relief medication regularly prior to visit 1~* Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation~* A diagnosis, treatment or remission of any cancer (other than basal cell carcinoma) within two years prior to visit 1~* Patients with chronic heart failure class III or IV (New York Heart Association)~* Suspected hypersensitivity and/or contraindication to any ingredients of the study medication (roflumilast, BDP, or salbutamol)~* A history of alcoholism or substance abuse within the 12 months prior to visit 1~* Pregnancy or women of childbearing potential who are not using a reliable method of contraception

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All consecutive statin-naive patients with non ST-elevation acute coronary syndrome admitted to our institution and scheduled for early invasive strategy are considered for enrollment~Exclusion Criteria:~* Current statin treatment~* High-risk features warranting emergency coronary angiography (within 2 hours)~* Acute renal failure or end-stage renal failure requiring dialysis or serum creatinine ≥ 3 mg/dl~* Severe comorbidities which precluded early invasive strategy~* Contraindications to statin treatment~* Contrast media administration within the last 10 days~* Pregnancy~* Refusal of consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: ACTIVE_COMPARATOR): Rosuvastatin (40 mg on-admission followed by 20 mg/day) until discharge; then 20 mg/day (10 mg/day if creatinine clearance \< 30 ml/min)
- Atorvastatin (Type: ACTIVE_COMPARATOR): atorvastatin (80 mg on-admission followed by 40 mg/day before and after discharge)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness Fluoride Varnishes in Children With Early Childhood Caries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of healthy children with severe early childhood caries,~* younger than 6 years in the primary dentition~Exclusion Criteria:~* history of any chronic disease,~* use of any drugs that reduce salivary flow or antibiotics in the last 4 weeks,~* use of systemic fluoride tablets

- Gender: ALL
- Minimum Age: 36 Months
- Maximum Age: 72 Months
- Healthy Volunteers: t

Study Arms:
- Sodium Fluoride (Type: ACTIVE_COMPARATOR): Varnish containing 5% Sodium Fluoride, was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
- Sodium Fluoride with TCP (Type: EXPERIMENTAL): Varnish containing 5% Sodium Fluoride with tricalcium phosphate (TCP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
- Sodium Fluoride with CXP (Type: EXPERIMENTAL): Varnish containing 5% Sodium Fluoride with Xylitol-coated Calcium and Phosphate (CXP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
- Sodium Fluoride with CPP-ACP (Type: EXPERIMENTAL): Varnish containing 5% Sodium Fluoride with casein phosphopeptide amorphous calcium phosphate (CPP-ACP), varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Sleep Duration and Vascular Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* recreationally active~* reporting no recent history of sleep problems~* not taking sleep-inducing medication~* not diabetic (fasting blood glucose \<126 mg/dL)~Exclusion Criteria:~* show symptoms of insomnia~* smoke~* have a personal history of stroke or diabetes~* take birth control pills

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- 8 hours time in bed (Type: EXPERIMENTAL): Participants will be asked to spend 8 hours time in bed with the aim of achieving one week of normal sleep duration (7 to 8 hours).
- 11 hours time in bed (Type: EXPERIMENTAL): Participants will be asked to spend 11 hours time in bed with the aim of achieving one week of long duration sleep as defined as 9+ hours of sleep.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is \>= 18 years of age~* Subject had a clinical diagnosis of chronic plaque psoriasis for at least 6 months, and has moderate to severe plaque psoriasis~* Subject must have been treated and failed to respond to, or has a contraindication to, or is intolerant to at least two different systemic therapies, one of which must be cyclosporine, or methotrexate or oral PUVA~* Subject is judged to be in generally good health as determined by the principal investigator~Exclusion Criteria:~* Subject has previous exposure to adalimumab~* Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy~* Subject is taking or requires oral or injectible corticosteroids~* Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced or medication-exacerbated psoriasis or new onset guttate psoriasis~* Subject considered by the investigator, for any reason, to be an unsuitable candidate~* Female subject who is pregnant or breast-feeding or considering becoming pregnant~* Subject has a calcium metabolism disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- adalimumab + placebo (Type: ACTIVE_COMPARATOR): adalimumab + placebo (vehicle ointment)
- adalimumab + calcipotriol/betamethasone (Type: ACTIVE_COMPARATOR): adalimumab + calcipotriol/betamethasone ointment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Argatroban in Critically Ill Patients With Heparin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient at risk for thrombosis or thromboembolic complications with the need of prophylactic antithrombotic therapy~* Age: 18 - 85 years~* Prohylactic anticoagulation (aPTT: 45 - 60 sec) is not achieved with a heparin dosage of 1.200 IU per hour after two hours of infusion~Exclusion Criteria:~* If patient needs an aPTT-level \> 60 sec for any reason~* Active bleeding~* Risk for bleeding higher than risk of thromboembolic event as anticipated by the physician~* Surgical procedure with the need for interruption of antithrombotic therapy within the next 24 hours~* Inevitable lethal course~* Severe Liver failure: Quick \< 30 %~* Pregnancy~* Planned peridural or spinal anaesthesia during the study~* Patient with known refusal of a participation in this clinical trial~* Active participation in another clinical trial~* Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study or confound the ability to interpret data from the study~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Standard Treatment (Type: NO_INTERVENTION): If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be contin-ued and, if necessary increased. Hereby the maximum heparin dose is 1.500 IU per hour.
- Treatment with Argatroban (Type: EXPERIMENTAL): If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be stopped and Argatroban will be given and adjusted until the target aPTT-range is achieved.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically proven diagnosis of non-small cell lung cancer~* positive for the ALK fusion gene (test provided by either a central laboratory. Local laboratory may be used for certain cases)~* may have received pemetrexed or docetaxel from previous Phase 3 trial (A8081007) and discontinued treatment due to Response Evaluation Criterion in Solid Tumors (RECIST)-defined progression. or, once the primary endpoint of Study A8081007 has been analyzed and the results made available, at any time without RECIST-defined progression.~* Tumors can be measurable or non measurable~Exclusion Criteria:~* prior treatment with PF-02341066~* received no prior systemic treatment, chemotherapy or EGFR tyrosine kinase inhibitor, for advanced non-small cell lung cancer~* current enrollment in another therapeutic clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-0231066 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Restoration® Modular Revision Hip System Post Market Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Candidates for cementless revision of a failed femoral prosthesis.~* Patients willing to sign the informed consent.~* Patients able to comply with follow-up requirements including post-operative weightbearing restrictions and self-evaluations.~* Male and non-pregnant female patients ages 18 to 85 years of age at the time of surgery.~Exclusion Criteria:~* Patients with ongoing infection.~* Patients who are severely immunocompromised.~* Patients who are prisoners.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Restoration® Modular (Type: OTHER): All subjects were enrolled into a single arm and received the Restoration® Modular Revision Hip System to replace the femoral portion of a failed previous implant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abatacept Post-marketing Clinical Study in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MTX inadequate responder~* Biologic Naïve~* Functional class I, II or III~* ≥6 swollen and ≥6 tender joints~* C-reactive protein (CRP) ≥2.0mg/dl or erythrocyte sedimentation rate (ESR) ≥28 mm/hr~* Anti-cyclic citrullinated peptide (CCP) antibody positive~* Have erosion~Exclusion Criteria:~* Any other rheumatic disease~* Active angiitis on main organs excluding rheumatoid nodule

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Abatacept + Methotrexate (MTX) (Type: EXPERIMENTAL): Abatacept 10 mg/kg solution intravenous (IV) infusion, once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months
- Group 2: Placebo matching with Abatacept + Methotrexate (Type: PLACEBO_COMPARATOR): Placebo matching with Abatacept 0 mg/kg solution, intravenous (IV) infusion once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination of Children Following Allogeneic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* pediatric recipient of allogeneic haematopoietic stem cell transplantation~* complete remission of underlying malignant disease (if applicable)~* stable haematopoietic engraftment~* Lansky-/Karnofsky-score \>= 60%~Exclusion Criteria:~* primary immunodeficiency~* hepatitis B or C, HIV infection~* application of radio-/ chemotherapy following stem cell transplantation~* extended chronic graft-versus-host disease (Karnofsky-scale \< 60%)~* coagulopathy~* known allergy/hypersensitivity towards ingredients of study vaccines~* seizure disorder, progressive neurologic disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA Positive and Genotype 1b~* No history or signs or symptoms of decompensated liver disease or hepatocellular carcinoma within 6 months~* A patient who is on dialysis, or if not MDRD eGFR\<30ml/min~* HCV treatment history: HCV treatment-naive participants, defined as never having received HCV treatment with any approved or investigational drug (including vaccines); OR HCV treatment-experienced, defined as having received previous HCV treatment with any (pegylated) interferon (\[Peg\]IFN)-based drug regimen (with or without ribavirin \[RBV\] and not including a direct-acting antiviral agent \[DAA\]). Last dose in this previous HCV treatment course should have occurred at least 2 months prior to screening~* No baseline mutation NS5A polymorphism including L31F/I/M/V and Y93H~Exclusion Criteria:~* A patient who having received Daclatasvir or Asunaprevir~* Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study~* Evidence of a medical condition contributing to chronic liver disease other than HCV or seropositive for HIV~* Diagnosed or suspected hepatocellular carcinoma or other malignancies~* Any history of, or current evidence of, clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage)~* Received solid organ or bone marrow transplant~* Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance~* Significant renal, cardiovascular, pulmonary, or neurological disease and uncontrolled diabetes or hypertension in the opinion of the investigator~* Known hypersensitivity to study drugs, metabolites, or formulation excipients~* Who has taken investigational drugs within 2 months.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daclatasvir plus Asunaprevir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aminophylline for Patients With Post-Dural Puncture Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* headache has developed after the dural puncture;~* PDPH was defined according to the International Classification of Headache Disorders III (ICHD-3) criteria;~* The VAS score of the headache was 5 or more than 5;~* age between 18 and 70 years old.~Exclusion Criteria:~* a previous history of headache that could interfere with PDPH diagnosis;~* a history of central nervous system diseases including intracranial hemorrhage, seizures, intracranial hypertension, and hydrocephalus;~* a history of cardiovascular system diseases including coronary heart disease, arrhythmias, and hypertension;~* a history of peptic ulcer.~* women who were pregnant, nursing, or planning a pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Aminophylline group (Type: EXPERIMENTAL): IV injection of aminophylline
- isotonic saline group (Type: PLACEBO_COMPARATOR): IV injection of isotonic saline group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Curcuma Domestica Extracts and Ibuprofen in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary osteoarthritis~* Knee pain score more than or equal to 5 point (NRS 0-10)~* Age \>= 50 years, not \> 75 years~* Knee crepitus~* Knee stiffness less than 30 minutes~* Urine pregnancy test negative in case of not being menopausal period~Exclusion Criteria:~* History of GI ulcer or melena~* Having hepatic or bile duct diseases(SGOT ≥ 37 u/L, SGPT ≥ 40 u/L)~* Having renal disease or abnormal renal functions (serum creatinine ≥ 1.5 mg/dl)~* Asthma or gout~* Allergy to ibuprofen or curcumin~* History of intraarticular knee injection within 6 months~* Post knee arthroplasty~* History of intermittent claudication~* Unable to walk, for example hemiplegia, severe lung/heart diseases~* Knee x-ray found chondrocalcinosis~* On anticoagulant

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- curcuma domestica (Type: EXPERIMENTAL): 1,500 mg/day (oral) divided into 3 times for 28 days
- Ibuprofen (Type: ACTIVE_COMPARATOR): 1,200 mg/day (oral) divided into 3 times for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete